Meeting Sponsors

Recognized as the global leader in robotic focal therapy, FocalTherics™ (NASDAQ: FOCL) develops, manufactures, and markets minimally invasive medical devices worldwide, leveraging focused ultrasound technology to treat a range of diseases.

The company's flagship product, the Focal One® Robotic HIFU system, combines advanced imaging, real-time treatment planning, robotic precision, and High-Intensity Focused Ultrasound (HIFU) technology to deliver personalized focal therapy designed to optimize clinical outcomes while preserving patients' quality of life.

FocalTherics is committed to advancing the clinical adoption of its proprietary robotic focused ultrasound solutions through continuous innovation, clinical evidence generation, physician education, and global market development initiatives.

HistoSonics is a growth-stage medical technology company developing a non-invasive sonic beam therapy platform based on the science of histotripsy, a breakthrough focused ultrasound technology originally developed by leading researchers at the University of Michigan.

Histotripsy uses focused sound energy to generate pressure that mechanically liquefies and destroys targeted tissue, including diseased tissue and tumors, at sub-cellular levels, without the need for incisions, radiation, or invasive surgery. The technology is designed to offer a non-invasive alternative to certain conventional treatment approaches while enabling greater precision and control.

The company's platform delivers personalized, tissue-specific treatments that aim to minimize many of the undesirable side effects associated with traditional interventional and surgical modalities. Through ongoing collaborations with leading clinicians and researchers, HistoSonics is advancing the translation of histotripsy from scientific innovation into everyday clinical practice.

Led by a team of experienced industry leaders, clinicians, and technology experts, HistoSonics is focused on expanding access to innovative image-guided therapies that improve patient outcomes and redefine standards of care. The company is headquartered in Plymouth, Minnesota, with additional offices in Ann Arbor, Michigan, and Madison, Wisconsin.

Cerno Health are the exclusive supplier to the NHS in England for Sonablate HIFU, the only HIFU equipment with twenty years of data for the treatment of prostate cancer, and the only HIFU equipment used in the recently released ten year outcome data for focal therapy using High Intensity Focused Ultrasound (HIFU) or Cryotherapy for nonmetastatic prostate cancer.

Cerno Health are a leading provider of Managed Healthcare Solutions (MES) serving the evolving needs of the international community. They represent a number of multinational companies including Sonablate, the world leader in High Intensity Focused Ultrasound (HIFU) for the treatment of prostate cancer.

Cerno Health are the Master Distributor for Sonablate in more than one hundred countries, including the United Kingdom, British Overseas Territories & Dependencies, the Caribbean countries & Brazil, Africa, the Middle East, Spain, Portugal, Slovakia, Cyprus, France, Vietnam, and Australia & New Zealand.

They focus on providing innovative products, superior service, and competitive pricing; supplying customers with technology which conforms to clearly established requirements and performance standards to guarantee long-term satisfaction.

Profound is a commercial-stage medical device company and an innovator in interventional MRI (iMRI) procedures. The company's flagship platform, TULSA-PRO®, enables MRI-guided, incision-free prostate ablation. Physicians use the TULSA Procedure™ to see, ablate, and confirm therapy in real time, supporting personalized treatment strategies across the continuum of prostate care—from whole-gland to subtotal, hemi, multifocal, and focal treatment. This approach enables individualized care using prostate tissue ablation, while minimizing the potential of the side effects that are typically associated with surgery or radiation, such as urinary incontinence and/or erectile dysfunction.

Profound also commercializes Sonalleve®, an MRI-guided therapy that provides a non-surgical treatment option for pain palliation of bone metastases, desmoid tumors, and osteoid osteoma, as well as for common gynecologic conditions including uterine fibroids and adenomyosis. Sonalleve delivers targeted therapy with no incisions, no blood loss during the procedure, no overnight hospital stay, and faster recovery — and, in gynecologic applications, enables uterine-sparing treatment that may help preserve fertility. Profound is also exploring additional clinical applications for Sonalleve, including non-invasive ablation of abdominal cancers and hyperthermia-based cancer therapies.

Through real-time MRI guidance and data-driven innovation, Profound is advancing the future of MRI-guided therapy — expanding access to precise, personalized, and incision-free treatment options worldwide.